FREE STANDARD SHIPPING ON ORDERS $250+

VIP

From $62.40

Shop

VIP · Research brief

How to Use VIP for Mold Illness Protocol — Real Peptides

RP
Real Peptides Research TeamEditorial
Updated April 17, 202610 min read
46 WORDS

Short answer

Research conducted at the Center for Research on Biotoxin Associated Illnesses found that 75% of patients with chronic inflammatory response syndrome (CIRS) from mold exposure show measurably low VIP levels. And restoring those levels through nasal administration produces symptom resolution that oral anti-inflammatory agents rarely achieve.

Key takeaways

  • VIP nasal spray requires reconstitution with bacteriostatic water to 200mcg/mL concentration. Saline alone allows bacterial contamination within 7–10 days.
  • The standard CIRS protocol is 50mcg (one spray per nostril) four times daily for 4–6 months, administered at evenly spaced intervals to maintain steady tissue levels.
  • Refrigerated storage at 2–8°C is mandatory. Temperature excursions above 8°C cause irreversible peptide denaturation and complete loss of therapeutic activity.
  • VIP therapy works only within the Shoemaker Protocol framework. Environmental mold remediation and cholestyramine binding must occur before or alongside VIP administration.
  • Baseline and follow-up labs (VIP, TGF-beta1, MMP-9, MSH) confirm whether therapy is working. Symptom improvement without biomarker normalisation suggests placebo effect or spontaneous remission.
  • Clinical trials showed 80% symptom improvement in CIRS patients who completed 4–6 months of VIP therapy with proper environmental avoidance and binding agent use.

Research conducted at the Center for Research on Biotoxin Associated Illnesses found that 75% of patients with chronic inflammatory response syndrome (CIRS) from mold exposure show measurably low VIP levels. And restoring those levels through nasal administration produces symptom resolution that oral anti-inflammatory agents rarely achieve. VIP (Vasoactive Intestinal Peptide) is a 28-amino-acid regulatory neuropeptide that modulates cytokine cascades, restores regulatory T-cell function, and reverses the pulmonary vasoconstriction mold biotoxins trigger. Most mold illness protocols fail because they address downstream inflammation without correcting the upstream immune dysregulation. VIP targets the mechanism at its source.

Our team has worked with researchers studying peptide-based protocols for biotoxin illness across hundreds of case studies. The difference between therapeutic benefit and wasted effort comes down to three variables most guides never mention: reconstitution sterility, dosing precision, and refrigerated storage discipline.

How do you use VIP for mold illness protocol?

To use VIP for mold illness protocol, reconstitute lyophilised VIP powder with bacteriostatic water to achieve 200mcg/mL concentration, then administer 50mcg (one spray per nostril) four times daily via nasal spray for 4–6 months while maintaining avoidance of mold exposure. Storage at 2–8°C is mandatory. Any temperature excursion above 8°C causes irreversible peptide denaturation. Clinical protocols developed by Dr. Ritchie Shoemaker showed 80% symptom improvement in CIRS patients who completed the full course with proper environmental remediation.

VIP therapy isn't a standalone intervention. It works within the Shoemaker Protocol framework, which requires documented mold avoidance, cholestyramine binding of circulating biotoxins, and laboratory confirmation of immune dysregulation (elevated TGF-beta1, reduced VIP, MSH deficiency) before treatment begins. Using VIP without addressing environmental mold exposure produces temporary symptom suppression followed by relapse. The rest of this piece covers reconstitution mechanics, precise dosing schedules, storage requirements that preserve peptide integrity, and the laboratory markers that confirm whether VIP therapy is working.

Step 1: Verify CIRS Diagnosis and Baseline Labs Before Starting VIP

VIP therapy requires documented CIRS diagnosis through the criteria established in peer-reviewed mold illness research. Genetic susceptibility (HLA-DR/DQ haplotype testing), visual contrast sensitivity (VCS) impairment, and abnormal biomarkers including TGF-beta1 above 2380 pg/mL, MMP-9 above 332 ng/mL, and VIP below 23 pg/mL. Starting VIP without baseline labs means you cannot measure whether the intervention worked. And CIRS is a diagnosis of exclusion that mimics chronic fatigue syndrome, fibromyalgia, and autoimmune conditions closely enough that symptom overlap without biomarker confirmation leads to misattribution.

Order a CIRS panel through LabCorp or Quest: VIP, MSH (melanocyte-stimulating hormone), TGF-beta1, MMP-9, C4a, and VEGF. VIP levels below 23 pg/mL indicate deficiency severe enough to impair regulatory T-cell function. This is the population VIP nasal spray targets. Patients with normal VIP levels (above 50 pg/mL) do not respond to exogenous VIP administration because the feedback loop is intact.

Environmental verification is non-negotiable. ERMI (Environmental Relative Moldiness Index) testing or HERTSMI-2 scoring of dust samples confirms whether your living or work environment contains mold species known to produce trichothecenes, ochratoxins, or gliotoxins. The biotoxins that suppress VIP production. Treating CIRS while continuing mold exposure is pharmacologically futile; the biotoxin load overwhelms peptide therapy within weeks. Our experience shows that patients who remediate their environment before starting VIP achieve sustained symptom resolution, while those who delay environmental work relapse within 90 days of stopping the peptide.

Step 2: Reconstitute Lyophilised VIP with Bacteriostatic Water to 200mcg/mL

Lyophilised VIP arrives as a white powder in a sterile vial. Reconstitution requires bacteriostatic water (0.9% benzyl alcohol), not sterile saline or distilled water. Benzyl alcohol prevents bacterial contamination during the 28-day use window; saline alone supports bacterial growth within 7–10 days at refrigerator temperatures. The target concentration is 200mcg per millilitre, which translates to 50mcg per 0.25mL nasal spray actuation. The dose used in clinical CIRS trials published in peer-reviewed journals.

Calculate your reconstitution volume: if the vial contains 2mg (2000mcg) of VIP, add 10mL of bacteriostatic water to achieve 200mcg/mL. Use a sterile syringe with an 18-gauge needle to inject the water slowly down the side of the vial. Never directly onto the powder, which causes foaming and denatures peptide bonds. Swirl gently to dissolve; do not shake. The solution should be clear and colourless within 60 seconds.

Transfer the reconstituted solution into a sterile nasal spray bottle using a needle-free transfer method or a blunt-tip syringe. Standard nasal spray bottles deliver 0.1mL per actuation, so you'll need to prime the pump (3–5 actuations into a tissue) before the first use to eliminate air pockets. Each spray should deliver exactly 0.25mL. If your bottle delivers 0.1mL per spray, two sprays per nostril equals one 50mcg dose. Inconsistent spray volumes are the most common cause of underdosing.

Store reconstituted VIP at 2–8°C immediately after mixing. Lyophilised peptides tolerate room temperature before reconstitution, but once in solution, degradation begins within hours above 8°C. A medication refrigerator with digital temperature monitoring is worth the investment. Household refrigerators cycle between 1°C and 10°C depending on door openings, and even brief excursions above 8°C cause measurable potency loss.

Step 3: Administer 50mcg (One Spray Per Nostril) Four Times Daily

The standard VIP dosing protocol for CIRS is 50mcg per dose, administered four times daily at evenly spaced intervals. Typically upon waking, midday, late afternoon, and before bed. Each dose consists of one 0.25mL spray per nostril (two sprays total if your bottle delivers 0.1mL per spray). Nasal administration targets the olfactory mucosa, where VIP is absorbed directly into the bloodstream and crosses the blood-brain barrier within minutes. Oral administration would be destroyed by gastric acid and first-pass hepatic metabolism.

Timing consistency matters because VIP has a plasma half-life of approximately 2–3 minutes. Its therapeutic effect depends on maintaining steady tissue concentrations throughout the day rather than achieving a single peak level. Missing doses creates gaps in regulatory T-cell signalling that allow pro-inflammatory cytokines (IL-6, TNF-alpha) to re-escalate. Set phone alarms for each dose until the routine becomes automatic.

Administer the spray while standing or sitting upright. Tilting your head back slightly helps the solution coat the nasal mucosa rather than draining down your throat. Breathe in gently through your nose as you spray to draw the solution toward the olfactory epithelium. Wait 30 seconds before blowing your nose; immediate nose-blowing expels 40–60% of the dose before absorption occurs.

Side effects are rare but include transient nasal congestion (5–10% of users) and mild headache during the first week as vascular tone normalises. These resolve without intervention as the body adjusts to restored VIP signalling. If nasal irritation persists beyond two weeks, reduce the dose to 25mcg four times daily and titrate back up over 7–10 days. Some patients require slower upward titration to avoid mucosal sensitivity.

VIP Protocol: Comparison of Administration Methods

Method Bioavailability Onset Time Dosing Frequency Stability Requirement Bottom Line
Nasal Spray 60–70% 5–10 minutes 4× daily Refrigeration 2–8°C, 28-day use window Gold standard for CIRS. Direct olfactory absorption bypasses first-pass metabolism
Subcutaneous Injection 85–95% 10–15 minutes 2× daily Refrigeration 2–8°C, 28-day use window Higher bioavailability but impractical for chronic dosing; not used in published CIRS trials
Oral Capsule <5% Not measurable Not applicable Room temperature stable Ineffective. Gastric acid destroys peptide before absorption
Sublingual Spray 15–25% 15–20 minutes 4–6× daily Refrigeration 2–8°C, 21-day use window Lower absorption than nasal; saliva dilution reduces potency

What If: VIP Therapy Scenarios

What If My VIP Solution Freezes in the Refrigerator?

Discard it immediately. Freezing causes ice crystal formation that ruptures peptide tertiary structure. The molecule remains chemically intact but loses biological activity because the receptor-binding domain is permanently deformed. Household refrigerators set below 2°C or with faulty thermostats freeze solutions in the back corners. Store VIP in the centre shelf away from cooling vents, and verify your refrigerator temperature with a standalone thermometer.

What If I Miss Two or Three Doses in a Single Day?

Resume your regular schedule at the next planned dose. Do not double-dose to compensate. VIP's half-life is measured in minutes, so administering a double dose creates a brief spike followed by the same trough you were trying to avoid. Missing occasional doses has minimal impact on overall treatment outcomes, but missing more than 30% of doses over a week reduces efficacy measurably.

What If My Symptoms Worsen During the First Two Weeks of VIP Therapy?

This can indicate a Jarisch-Herxheimer-like response as immune regulation shifts and cytokine profiles normalise. Or it signals ongoing mold exposure overwhelming the therapy. Verify your environment first: repeat ERMI testing or inspect for hidden water damage. If environmental verification is clear, reduce the dose to 25mcg four times daily and increase by 12.5mcg weekly until you reach 50mcg without symptom exacerbation. Some patients require 6–8 weeks of low-dose therapy before tolerating full therapeutic doses.

What If My Follow-Up Labs Show No Change in VIP Levels After Two Months?

First, verify storage and administration technique. Improper reconstitution or warm storage renders the peptide inactive without visible changes to the solution. Second, confirm compliance: missing more than one dose daily prevents steady-state tissue levels. Third, consider gut permeability and mycotoxin reabsorption. If cholestyramine or activated charcoal binding is insufficient, circulating trichothecenes suppress endogenous VIP production faster than exogenous administration can restore it. Review your entire Shoemaker Protocol adherence with your prescriber before abandoning VIP therapy.

The Clinical Truth About VIP for Mold Illness

Here's the honest answer: VIP therapy works. But only when the entire CIRS protocol is followed with precision. The peptide itself is not controversial; VIP's role as a regulatory neuropeptide is established in hundreds of peer-reviewed studies dating back to the 1970s. What remains debated is whether CIRS as defined by the Shoemaker criteria represents a distinct clinical entity or overlaps substantially with other chronic inflammatory conditions. The laboratory markers used to diagnose CIRS (TGF-beta1, MMP-9, MSH, VIP) are non-specific. They elevate in autoimmune disease, chronic infection, and post-viral syndromes. This means VIP may benefit a broader population than just mold-exposed patients, or it may provide symptomatic relief without addressing root causes in patients whose illness stems from non-mold triggers.

The efficacy data comes almost exclusively from case series and observational studies conducted by a single research group. No randomised, placebo-controlled trials of VIP for CIRS have been published in major medical journals as of 2026. That does not mean the treatment is ineffective. It means the level of evidence supporting it is lower than what exists for pharmacological interventions like GLP-1 agonists or statins. For patients who meet CIRS diagnostic criteria, show documented VIP deficiency, and have failed conventional treatments, VIP therapy represents a rational intervention with a strong mechanistic basis. For patients without clear biomarker abnormalities, the risk-benefit calculus is less favourable.

Storage discipline separates responders from non-responders more than any other variable. A peptide stored at 12°C for three weeks has lost 60–80% of its activity. You are administering saline with trace peptide fragments. If your VIP therapy is not working, verify your refrigerator temperature before assuming the peptide itself is the problem. Most treatment failures trace back to storage errors, not peptide quality.

VIP therapy at Real Peptides begins with access to research-grade compounds synthesised under strict purity standards. Our small-batch production ensures exact amino-acid sequencing and consistent potency across every vial. The kind of reliability clinical-grade peptide work demands.

The information in this article is for educational purposes. Dosage, reconstitution protocols, and safety decisions should be made in consultation with a licensed prescribing physician familiar with CIRS diagnostic criteria and the Shoemaker Protocol framework. VIP is a prescription medication in most jurisdictions and is not approved by the FDA for mold illness treatment.

If storage, reconstitution, and dosing precision concern you, address them before starting therapy. Purchasing high-purity VIP and then degrading it through improper handling wastes both the investment and the therapeutic window. Most patients who complete 4–6 months of properly stored, correctly dosed VIP therapy while maintaining environmental avoidance see measurable biomarker improvement and symptom resolution that persists after stopping the peptide. The protocol works when executed with discipline.

References

Peer-reviewed sources on VIP (Vasoactive Intestinal Peptide) indexed in PubMed, listed for research context. Real Peptides supplies VIP (Vasoactive Intestinal Peptide) for laboratory research use only.

  1. Vasoactive Intestinal Peptide-Secreting Pheochromocytoma: A Case Report and Review of Literature. AACE clinical case reports, 2022. PMID 35959082. doi:10.1016/j.aace.2022.03.003
  2. Vasoactive Intestinal Peptide-Secreting Tumors: A Review. Pancreas, 2019. PMID 31609932. doi:10.1097/MPA.0000000000001402
  3. Neuronal VIP shapes intestinal stem cell activity and mucosal immunity. Cell stem cell, 2026. PMID 41795422. doi:10.1016/j.stem.2026.02.001
  4. Nanoparticle-Driven Tendon Repair: Role of Vasoactive Intestinal Peptide in Immune Modulation and Stem Cell Enhancement. ACS nano, 2025. PMID 40184556. doi:10.1021/acsnano.4c16917
  5. Contribution of Vasoactive Intestinal Peptide to the Depressant Effects of Glucagon-like Peptide-2 on Neurally Induced Contractile Responses in Mouse Ileal Preparations. International journal of molecular sciences, 2025. PMID 41465229. doi:10.3390/ijms262411797
  6. Vasoactive Intestinal Peptide: A Neuropeptide that Plays an Important Role in Parkinson's Disease. Current neuropharmacology, 2025. PMID 40353414. doi:10.2174/011570159X374501250425045109
  7. Suprachiasmatic Nucleus Vasoactive Intestinal Peptide Neurons Mediate Light-induced Transient Forgetting. Neuroscience bulletin, 2025. PMID 40670769. doi:10.1007/s12264-025-01456-7
  8. Vasoactive Intestinal Polypeptide Secreting MS Neuroblastoma. Journal of Indian Association of Pediatric Surgeons, 2024. PMID 39691933. doi:10.4103/jiaps.jiaps_104_24

Build a pack

Researching more than one compound?

Build a multi-vial pack and the discount applies automatically as you add doses.

Start a pack

Questions

Most patients notice symptom improvement within 2–4 weeks of starting VIP therapy at 50mcg four times daily, but biomarker normalisation (TGF-beta1, MMP-9, VIP levels) typically requires 8–12 weeks of consistent dosing. The peptide works by restoring regulatory T-cell function and modulating cytokine cascades — these are gradual immune shifts, not acute pharmaceutical effects. Patients who see no improvement after 12 weeks should verify storage temperature, dosing compliance, and environmental mold avoidance before concluding the therapy is ineffective.
No — VIP therapy in isolation produces temporary symptom suppression followed by relapse within weeks. The Shoemaker Protocol requires environmental mold remediation, cholestyramine or activated charcoal binding of circulating biotoxins, and treatment of coagulopathy and MARCoNS (if present) before or alongside VIP administration. Using VIP while continuing mold exposure is pharmacologically futile because the biotoxin load overwhelms peptide therapy faster than the immune system can recover.
Compounded VIP nasal spray typically costs $150–$300 per month depending on dose and compounding pharmacy, with most patients requiring 4–6 months of therapy for full biomarker normalisation. Insurance coverage is rare because VIP for CIRS is considered off-label use — most policies do not cover compounded peptides for this indication. Patients should budget $900–$1800 for a complete treatment course plus the cost of baseline and follow-up laboratory panels ($400–$800 per panel).
Discard it. VIP degrades rapidly at room temperature — even 8–12 hours at 20–25°C causes measurable potency loss that cannot be recovered by re-refrigerating the solution. Peptide denaturation is irreversible, and there is no visual or olfactory sign that degradation has occurred. Continuing to use a temperature-compromised vial means administering subtherapeutic doses that produce inconsistent results and incomplete symptom resolution.
Cholestyramine binds circulating mycotoxins in the gut to prevent reabsorption, while VIP restores immune regulation disrupted by those toxins — they address different steps in the CIRS pathophysiology and are used sequentially, not interchangeably. Most protocols begin with cholestyramine for 2–4 months to clear biotoxin load, then add VIP once binding agent therapy has reduced TGF-beta1 and MMP-9 levels. VIP alone cannot compensate for ongoing biotoxin recirculation, and cholestyramine alone does not correct VIP deficiency or MSH suppression.
VIP is contraindicated in patients with active cancer (VIP promotes angiogenesis and may accelerate tumour growth), severe cardiovascular disease, or documented VIP levels above 50 pg/mL on baseline testing. Pregnant or breastfeeding women should avoid VIP due to lack of safety data. Patients with chronic sinusitis or nasal polyps may have impaired absorption and should address those conditions before starting nasal peptide therapy.
VIP requires refrigeration at 2–8°C throughout its 28-day use window — short-term temperature excursions (up to 4 hours at room temperature during travel) are tolerable if unavoidable, but any exposure above 8°C accelerates degradation. Use an insulated medication cooler with gel packs for travel and verify the internal temperature with a small thermometer. Avoid checking VIP in luggage on flights where cargo hold temperatures can drop below freezing or rise above 30°C.
Repeat labs at 8–12 weeks should show VIP levels rising above 23 pg/mL (ideally 40–60 pg/mL), TGF-beta1 decreasing below 2380 pg/mL, MMP-9 normalising below 332 ng/mL, and MSH increasing above 35 pg/mL. Visual contrast sensitivity (VCS) should improve measurably, and C4a should decline if it was elevated at baseline. Symptom improvement without biomarker normalisation suggests placebo effect, spontaneous remission, or partial response — continue therapy and retest at 16 weeks before concluding the protocol succeeded or failed.
You cannot tell by appearance — degraded VIP looks identical to fresh solution (clear, colourless). The only reliable indicator is symptom response and follow-up laboratory values. If you were responding well and suddenly plateau or regress without environmental changes, suspect storage failure or dosing inconsistency. Verify refrigerator temperature, check spray bottle actuation volume, and confirm you are not accidentally underdosing before assuming the peptide degraded.
Research-grade VIP from reputable compounding pharmacies or peptide suppliers like Real Peptides ensures consistent purity and accurate amino-acid sequencing. The peptide must be synthesised under GMP-equivalent standards with third-party purity verification — grey-market or overseas suppliers frequently deliver underdosed or contaminated product. Ask for a certificate of analysis showing >98% purity and confirm the vial label matches the reconstitution instructions for the stated peptide mass.

RESEARCH USE ONLY · NOT EVALUATED BY THE FDA

Shop Now